Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its ... comprises the Phase II ...

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for ... "Just three years after filing an ...

Notably, the successful completion of the FDA End of Phase ... the drug’s favorable cardiac efficacy. This positions Altimmune advantageously against competitors, with no significant safety concerns.

Not only does this cause tiredness, but it can also increase the risk of high blood pressure, stroke, heart disease and ...

A new clinical study shows that an inhibitor of Fas ligand ... randomised, open-label, controlled, phase 2 trial’ has been published in eClinicalMedicine. The physiological role of FasL is to keep ...